Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts

HRSA has referred six drug manufacturers to the HHS Office of Inspector General for refusing to offer 340B discounts in the contract pharmacy setting.

The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (OIG) regarding their refusal to offer 340B program discounts to 340B covered

Read More »

Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule

Former President Trump signed an executive order in July 2020 directing HHS to limit what 340B health centers can charge patients for insulin and EpiPen-type devices.

The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.

Please Login or Become a

Read More »

Arkansas Insurance Dept. to Rule Next Month on PhRMA’s Petition to Block Novel 340B Contract Pharmacy Law

An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements.

An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements pending resolution of a bevy of federal lawsuits

Read More »

Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Please Login or Become a Paid

Read More »

In Largely Symbolic Move, Becerra Expresses “Strong Support” for 340B in Drug Pricing Plan

HHS Secretary Xavier Becerra yesterday expressed "strong support" for the 340B program in a drug pricing report to the White House, but recommended no changes to the program.

U.S. Health and Human Services Secretary Xavier Becerra yesterday reiterated HHS’ “strong support for the 340B Drug Pricing Program” in a 29-page plan to lower drug prices.

Please Login or Become a Paid Subscriber to View

Read More »

As Hospital Recertification Deadline Nears, 340B Eligibility Challenges Appear Not to Be Widespread for Now

The COVID-19 pandemic’s impact on hospitals’ eligibility for 340B could become an issue beginning later this year, industry observers say.

With the deadline for hospitals to recertify their eligibility for 340B drug discounts arriving on Monday, it appears most facilities will remain qualified—at least for now.

Please Login or Become a Paid Subscriber to View this

Read More »

Hearing Friday on PhRMA’s Push to Quash First State Law to Protect 340B Contract Pharmacy Program

Arkansas Insurance Commissioner Alan McClain temporarily suspended his state's new 340B contract pharmacy law pending a review of its constitutionality.

The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by

Read More »

After HRSA Notification, NACHC Refiles 340B Dispute Complaints Against Drug Manufacturers

Community health centers split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together.

Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.

Read More »

Medicare Trustees Say Part B Drug Payments Will More than Double by 2030

The Medicare Board of Trustees expects Part B reimbursement for physician-administered drugs will more than double to $46.2 billion by 2030.

Medicare Part B reimbursement for physician-administered drugs is projected to rise from $18.7 billion in 2020 to $21.7 billion this year, and then to more than double to $46.2 billion by 2030, the Medicare Board of Trustees reported to Congress

Read More »
Generic selectors
Exact matches only
Search in title
Search in content